fimosudil   Click here for help

GtoPdb Ligand ID: 14620

Synonyms: TDI01 | TDI01470
PDB Ligand
Compound class: Synthetic organic
Comment: Fimosudil is the INN for a Rho-associated protein kinase (ROCK) inhibitor that was included in WHO INN Proposed List 135 (July 2026). Analysis of the available information, including from the RCSB Protein Data Bank, suggests that this is likely the INN for Beijing Tide Pharmaceutical's selective ROCK2 inhibitor TDI01 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 84.69
Molecular weight 485.49
XLogP 2.21
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C2=C(C=CC(=C2)C3=NC(=CC=N3)NC4=CC=C(C=C4)C5=CNN=C5)C=C1C(=O)N6CC(C6)(F)F
Isomeric SMILES CN1C(=CC2=C1C=C(C=C2)C3=NC=CC(=N3)NC4=CC=C(C=C4)C5=CNN=C5)C(=O)N6CC(C6)(F)F
InChI InChI=1S/C26H21F2N7O/c1-34-21-11-18(3-2-17(21)10-22(34)25(36)35-14-26(27,28)15-35)24-29-9-8-23(33-24)32-20-6-4-16(5-7-20)19-12-30-31-13-19/h2-13H,14-15H2,1H3,(H,30,31)(H,29,32,33)
InChI Key GWMOTZHLJFWMIZ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
TDI01 was progressed as a clinical candidate for potential to treat idiopathic pulmonary fibrosis (IPF) and chronic graft-versus-host disease (cGVHD). It is proposed to block-ROCK2-mediated fibrotic tissue/organ damage.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06169722 TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) Phase 1/Phase 2 Interventional Beijing Tide Pharmaceutical Co., Ltd
NCT07464912 A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Phase 3 Interventional Beijing Tide Pharmaceutical Co., Ltd